What's Happening?
Researchers at the University of North Carolina at Chapel Hill are exploring a novel approach to cancer treatment that aims to reduce the chronic side effects often associated with traditional therapies. Led by Brianna Vickerman, a research assistant
professor at the UNC Eshelman School of Pharmacy, the team is developing a method that uses light to activate cancer drugs only at the disease site. This technique involves encapsulating existing medications into carriers that circulate through the body without affecting healthy tissues. When the disease area is illuminated, the carriers release the drug precisely where needed. This approach builds on previous research involving light-controlled drug delivery for cardiovascular diseases. The project recently received a two-year commercialization-focused innovation grant to further test the technology in cancer models, with the ultimate goal of clinical development.
Why It's Important?
The significance of this research lies in its potential to transform cancer treatment by reducing the adverse side effects that patients often endure. Traditional cancer therapies can lead to long-term complications such as nerve damage and hearing loss, impacting patients' quality of life. By targeting drugs specifically to cancerous tissues, this new method could allow for effective treatment without the collateral damage to healthy cells. This advancement could benefit patients with head and neck cancers, where current treatments are particularly harsh. The innovation grant provides crucial funding to advance this research, potentially leading to safer and more effective cancer therapies. If successful, this approach could also be applied to other diseases, such as cardiovascular conditions, broadening its impact on healthcare.
What's Next?
The research team plans to continue testing the light-activated drug delivery system in cancer models, with the long-term aim of moving towards clinical trials. The innovation grant will support these efforts, enabling the team to refine the technology and assess its efficacy and safety. Looking ahead, Vickerman envisions the application of this technology in clinical settings within the next decade, offering patients a safer alternative to current treatments. The success of this project could prompt further research into light-activated therapies for various medical conditions, potentially revolutionizing the way diseases are treated.
